John S. Condeelis

University of North Carolina at Chapel Hill — United States

Medicine · Health Sciences

116h-index45.3kcitations642works1.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Cells and Metastasis(201), Cellular Mechanics and Interactions(200), Cell Adhesion Molecules Research(69), Immune cells in cancer(68), HER2/EGFR in Cancer Research(60)

Publications642 total

Nonlinear imaging histopathology: a method to correlate the gold-standard hematoxylin and eosin staining with modern nonlinear microcopy (Erratum)
2025
Optogenetic control of cofilin and αTAT in living cells using Z-lock
UNC Libraries·2025Open Access
Author Correction: Optogenetic control of cofilin and αTAT in living cells using Z-lock
UNC Libraries·2025Open Access
Detection of TMEM Doorways and Their Activity Required for Metastasis
2025
Targeting CSF-1 signaling between tumor cells and macrophages at TMEM doorways inhibits breast cancer dissemination
Oncogene·2025· 4 citedOpen Access
Corrections to “Nonlinear Imaging Histopathology: A Pipeline to Correlate Gold-Standard Hematoxylin and Eosin Staining With Modern Nonlinear Microscopy”
IEEE Journal of Selected Topics in Quantum Electronics·2025
Abstract P1-04-16: Racial Disparities in the Pro-Metastatic Tumor Microenvironment of Treatment-Naive Breast Cancer
Clinical Cancer Research·2025
Supplementary Figure S6 from Phase Ib Clinical and Pharmacodynamic Study of the TIE2 Kinase Inhibitor Rebastinib with Paclitaxel or Eribulin in HER2-Negative Metastatic Breast Cancer
2025Open Access
Supplementary Figure S2 from Phase Ib Clinical and Pharmacodynamic Study of the TIE2 Kinase Inhibitor Rebastinib with Paclitaxel or Eribulin in HER2-Negative Metastatic Breast Cancer
2025Open Access
Supplementary Figure S5 from Phase Ib Clinical and Pharmacodynamic Study of the TIE2 Kinase Inhibitor Rebastinib with Paclitaxel or Eribulin in HER2-Negative Metastatic Breast Cancer
2025Open Access
Supplementary Table S4 from Phase Ib Clinical and Pharmacodynamic Study of the TIE2 Kinase Inhibitor Rebastinib with Paclitaxel or Eribulin in HER2-Negative Metastatic Breast Cancer
2025Open Access
Supplementary Figure S7 from Phase Ib Clinical and Pharmacodynamic Study of the TIE2 Kinase Inhibitor Rebastinib with Paclitaxel or Eribulin in HER2-Negative Metastatic Breast Cancer
2025Open Access
Supplementary Figure S3 from Phase Ib Clinical and Pharmacodynamic Study of the TIE2 Kinase Inhibitor Rebastinib with Paclitaxel or Eribulin in HER2-Negative Metastatic Breast Cancer
2025Open Access
Supplementary Table S6 from Phase Ib Clinical and Pharmacodynamic Study of the TIE2 Kinase Inhibitor Rebastinib with Paclitaxel or Eribulin in HER2-Negative Metastatic Breast Cancer
2025Open Access
Supplementary Table S3 from Phase Ib Clinical and Pharmacodynamic Study of the TIE2 Kinase Inhibitor Rebastinib with Paclitaxel or Eribulin in HER2-Negative Metastatic Breast Cancer
2025Open Access
Supplementary Table S1 from Phase Ib Clinical and Pharmacodynamic Study of the TIE2 Kinase Inhibitor Rebastinib with Paclitaxel or Eribulin in HER2-Negative Metastatic Breast Cancer
2025Open Access
Supplementary Figure S4 from Phase Ib Clinical and Pharmacodynamic Study of the TIE2 Kinase Inhibitor Rebastinib with Paclitaxel or Eribulin in HER2-Negative Metastatic Breast Cancer
2025Open Access
Supplementary Figure S9 from Phase Ib Clinical and Pharmacodynamic Study of the TIE2 Kinase Inhibitor Rebastinib with Paclitaxel or Eribulin in HER2-Negative Metastatic Breast Cancer
2025Open Access
Supplementary Figure S8 from Phase Ib Clinical and Pharmacodynamic Study of the TIE2 Kinase Inhibitor Rebastinib with Paclitaxel or Eribulin in HER2-Negative Metastatic Breast Cancer
2025Open Access
Supplementary Table S5 from Phase Ib Clinical and Pharmacodynamic Study of the TIE2 Kinase Inhibitor Rebastinib with Paclitaxel or Eribulin in HER2-Negative Metastatic Breast Cancer
2025Open Access
page 1 of 33Next →

Frequent Co-authors

Jeffrey Wyckoff(11), Jeffrey E. Segall(11), Robert J. Eddy(7), Jeffrey W. Pollard(6), David Entenberg(6), Hideki Yamaguchi(5), Yarong Wang(5), Sumanta Goswami(5), Erik Sahai(5), Robert H. Singer(5), Joan G. Jones(5), Weigang Wang(5), Jose Javier Bravo‐Cordero(5), Allison S. Harney(4), Vera DesMarais(4), Antonia Patsialou(3), Mousumi Ghosh(3), Xiaoyan Song(3), Ghassan Mouneimne(3), Mazen Sidani(3)